A5054491719- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Ovarian cancer diagnosis and treatment
- Inflammatory Biomarkers in Disease Prognosis
- Pancreatic and Hepatic Oncology Research
- Phagocytosis and Immune Regulation
- Cancer-related Molecular Pathways
- Immunotherapy and Immune Responses
- Advanced Radiotherapy Techniques
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Breast Lesions and Carcinomas
- Monoclonal and Polyclonal Antibodies Research
- Sarcoma Diagnosis and Treatment
- Cancer Research and Treatments
- RNA modifications and cancer
- interferon and immune responses
- Neuroblastoma Research and Treatments
- Reproductive Biology and Fertility
- Gut microbiota and health
Université Clermont Auvergne
2013-2024
Inserm
2016-2024
Centre Jean Perrin
2015-2024
Imagerie Moléculaire et Stratégies Théranostiques
2016-2023
Clermont Université
2019-2021
Memorial Sloan Kettering Cancer Center
2014
Massachusetts General Hospital
2014
Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidylinositol 3-kinase (PI3K)-Akt pathway are common therapeutically targeted in triple-negative breast cancer (TNBC). However, activation another EGFR family member [human 3 (HER3) (or ErbB3)] may limit antitumor effects these drugs. We found that TNBC cell lines cultured with HER3 ligand EGF heregulin, respectively, treated either an Akt inhibitor (GDC-0068) a PI3K (GDC-0941) had increased...
Purpose: AXL receptor tyrosine kinase has been described as a relevant molecular marker and key player in invasiveness, especially triple-negative breast cancer (TNBC).Experimental Design: We evaluate the antitumor efficacy of anti-AXL monoclonal antibody 20G7-D9 several TNBC cell xenografts or patient-derived xenograft (PDX) models decipher underlying mechanisms. In dataset 254 basal-like samples, genes correlated with expression are enriched EMT, migration, invasion signaling...
The hypermetabolic nature of cancer cells and their increased reliance on "aerobic glycolysis", as originally described by Otto Warburg colleagues, are considered metabolic hallmarks cells. BRCA1 is a major tumor suppressor in breast it was implicated numerous pathways resulting anticarcinogenic functions. objective our study to address specific contributions the features cells, including so-called "Warburg effect". To get comprehensive approach role cell metabolism, we performed global...
Abstract Patient stratification has been instrumental for the success of targeted therapies in breast cancer. However, molecular basis metastatic cancer and its therapeutic vulnerabilities remain poorly understood. Here we show that PML is a novel target aggressive The acquisition aggressiveness features tumours accompanied by elevated expression enhanced sensitivity to inhibition. Interestingly, find STAT3 responsible, at least part, transcriptional upregulation Moreover, targeting hampers...
Proteins normally localized in the intracellular compartments of healthy cells, have been observed at surface cancer despite not having transmembrane domain or secretion signals. The unexpected localization these externalized proteins is likely to reflect currently unknown functions. Their presence on cell presents a unique opportunity for therapy, enabling development antibody- peptide-based strategies. In this study, we demonstrate an extracellular form ribosomal protein L21 (eL21) triple...
Systemic therapy for triple negative breast cancer (TNBC) is mostly based upon chemotherapy. Epithelial Growth Factor Receptor (EGFR) overexpressed in around 50% of TNBC and may play a role its pathogenesis. Consequently, we performed multicentric pilot Phase II neoadjuvant trial cetuximab (anti-EGFR antibody) combined with docetaxel patients operable, Stage II-III TNBC. Therapy consisted weekly (first infusion: 400 mg/m(2), then 250 mg/m(2)) six cycles (T: 100 q.3 weeks. Subsequently, all...
// Gaëlle Thomas 1,2 , Thierry Chardès 1 Nadège Gaborit Caroline Mollevi 5 Wilhem Leconet Bruno Robert Nina Radosevic-Robin 3 Frédérique Penault-Llorca Céline Gongora Pierre-Emmanuel Colombo Yassamine Lazrek 1,4 Rui Bras-Goncalves Ariel Savina 6 David Azria Hervé Bazin 7 André Pèlegrin and Christel Larbouret IRCM, Institut de Recherche en Cancérologie Montpellier, F-34298, France; INSERM, Unit 896, Université Montpellier1, ICM, France 2 Roche et Médecine Translationnelle, Boulogne...
Tumour-infiltrating lymphocytes (TILs) have been demonstrated to significantly influence prognosis and response therapy of invasive breast cancer (IBC). Thus, it has suggested that TIL density or/and immunophenotype could serve as biomarkers for selection IBC patients immunotherapy. However, much less is known about significance TILs in ductal carcinoma situ (DCIS). We retrospectively investigated 96 pure DCIS 35 microinvasive carcinomas (miCa). was assessed on H&E-stained biopsy sections...
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer characterized by poor response to chemotherapy and radiotherapy due the lack of efficient therapeutic tools early diagnostic markers. We previously generated nonligand competing anti-HER3 antibody 9F7-F11 that binds pancreatic tumor cells induces regression in vivo experimental models. Here, we asked whether coupling with a radiosensitizer, such as monomethylauristatin E (MMAE), using antibody-drug conjugate (ADC) technology...